Altasciences is expanding its facility in Columbia, Missouri to provide bioanalytical services in support of preclinical and clinical studies conducted in the US.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes.
Altasciences’ acquisition of a preclinical testing business marks the “next major milestone” in the CRO’s goal to provide an integrated offering from lead candidate selection to proof of concept.